Meritage Portfolio Management Grows Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Meritage Portfolio Management boosted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60,398 shares of the specialty pharmaceutical company’s stock after buying an additional 1,595 shares during the quarter. Meritage Portfolio Management owned approximately 0.11% of Supernus Pharmaceuticals worth $1,904,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new stake in Supernus Pharmaceuticals in the first quarter worth $41,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Supernus Pharmaceuticals in the first quarter valued at $46,000. GAMMA Investing LLC grew its position in shares of Supernus Pharmaceuticals by 116.7% in the second quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,541 shares in the last quarter. CWM LLC grew its position in shares of Supernus Pharmaceuticals by 92.4% in the second quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock valued at $97,000 after purchasing an additional 1,479 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Supernus Pharmaceuticals in the first quarter valued at $103,000.

Supernus Pharmaceuticals Stock Down 1.0%

Shares of SUPN stock opened at $49.00 on Monday. The business has a 50-day moving average price of $44.96 and a two-hundred day moving average price of $36.73. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $51.78. The firm has a market cap of $2.75 billion, a P/E ratio of 42.61 and a beta of 0.78.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $45.87, for a total transaction of $229,350.00. Following the completion of the sale, the senior vice president owned 15,496 shares of the company’s stock, valued at $710,801.52. The trade was a 24.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $44.49, for a total value of $524,092.20. Following the sale, the chief financial officer directly owned 1,246 shares of the company’s stock, valued at approximately $55,434.54. This trade represents a 90.43% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 362,741 shares of company stock valued at $16,390,592 over the last 90 days. Insiders own 8.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Piper Sandler upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $40.00 to $65.00 in a research report on Thursday. Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 17th. Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research report on Tuesday, September 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $64.00.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.